Premium
Oncogenes, breast cancer, and chemoprevention
Author(s) -
Liu Edison T.
Publication year - 1993
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.240531130
Subject(s) - breast cancer , biology , cancer research , cancer , ductal carcinoma , germline , point mutation , oncogene , oncology , mutation , medicine , gene , genetics , cell cycle
Perturbations of oncogenes in breast carcinoma include amplifications of the HER‐2/ neu and PRAD1 genes, as well as p53 mutations. Some of these lesions frequently appear in early cancers such as ductal carcinoma in situ and are stable as the tumors become invasive and metastasize. Thus these findings suggest that oncogene mutations may define a point of origin for a given breast cancer, and are fixed lesions during tumor progression. Such germline abnormalities may occur at the BRCA1, HRAS VNTR, and p53 loci. The rational use of genetics may be to identify women at high risk for the development of breast cancer so that they may be enrolled in future chemoprevention trials.